The Economic Burden of Anti-Vascular Endothelial Growth Factor on Patients and Caregivers in the UK, Europe, and North America
More durable therapies for nAMD/DME would reduce treatment burden and have a sizeable impact financially on patients with nAMD/DME and their caregivers.
Authors
- Ayesha Ahmed (ORCID: https://orcid.org/0000-0002-2036-7067)
- Arjun Watane (ORCID: https://orcid.org/0000-0003-2104-9949)
- Oliver Cox (ORCID: https://orcid.org/0000-0002-2308-7837)
- David Tabano (ORCID: https://orcid.org/0000-0001-7657-0809)
- Louise Longworth (ORCID: https://orcid.org/0000-0003-2512-4862)
- Sarah Hill (ORCID: https://orcid.org/0000-0002-5408-2473)
- Yemi Oluboyede (ORCID: https://orcid.org/0000-0002-9891-8279)
- Nimesh Patel (ORCID: https://orcid.org/0000-0002-6021-9421)
- Richard Peter Gale (ORCID: https://orcid.org/0000-0002-8847-044X)
Institutions
- Roche (Switzerland) (CH)
- Harvard University (US)
- Yale University (US)
- Gene Therapy Laboratory (FR)
- York Teaching Hospital NHS Foundation Trust (GB)
- University of York (GB)
- Hull York Medical School (GB)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-06-28
- DOI
- https://doi.org/10.1007/s40123-025-01180-5
- Citations
- 6
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.24
Funders
- F. Hoffmann-La Roche